MIAMI--(BUSINESS WIRE)--Alz1, a brand of Igea Pharma (IGPH:SIX Swiss Ex) focused on reinventing proactive healthcare in Alzheimer’s disease, today announced the launch of Alz1, the first solution designed to detect and reduce high free copper levels in the bloodstream — a risk factor associated with Alzheimer's disease — through a first-of-its-kind in-home blood test and dietary supplement for those with elevated free copper levels.1
“The digital revolution has sparked a shift in the way consumers think about and access healthcare,” said Diego Mortillaro, CEO at Igea Pharma. “Our revolutionary Alz1 solution empowers consumers with the information they need to take steps now that can reduce a major risk factor for Alzheimer’s disease.”
The Alz1 Kit, available exclusively online, is an easy-to-use in-home blood collection kit designed to measure free copper, a modifiable risk factor that can contribute to the onset and progression of Alzheimer’s disease. Through the identification of free copper, the test empowers users to take proactive control — like lifestyle and dietary changes — of their health and well-being. With no doctor’s appointment, prescription or need to bill insurance, Alz1 ensures this area of strategic proactive healthcare is easier than ever.
If results shared exclusively with users through Alz1’s secure online platform show high free copper levels, users have the option to order the Alz1 Tab, a natural dietary supplement designed to reduce and control heavy metal contents in the bloodstream, including free copper. Containing glutathione and oleuropein, among other ingredients, the Alz1 Tab could be useful in protecting against neurodegeneration.
“In recent years, several of the most promising programs to develop drugs for the treatment of Alzheimer’s disease failed,” said Mortillaro. “Compounding the issue, the Alzheimer’s Association revealed that the number of Americans who have Alzheimer’s is expected to more than double by 2050. Our mission is to find better, more convenient ways to help consumers have a positive impact on proven risk factors of Alzheimer’s.”
For more information about the Alz1 solution or why detecting free copper in the bloodstream is important, please visit https://alz1.com/.
Alz1, a Miami-based brand of Igea Pharma, leverages the deep scientific knowledge of Igea Pharma’s scientific advisory board to reinvent proactive healthcare in Alzheimer’s disease by capitalizing on digital economy opportunities and recent healthcare industry trends. The simple and convenient Alz1 Kit is an at-home blood test designed to detect free copper in the bloodstream — high levels of which indicate one of the risk factors for Alzheimer’s disease. The Alz1 Tab, a natural dietary supplement, helps decrease heavy metal contents, including free copper, in the bloodstream. For information, visit https://alz1.com/.
Certain information set forth in this document may contain forward-looking statements. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. The company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.
1These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.